Entering text into the input field will update the search result below

BioLineRx nabs rights to DES candidate from Hebrew University

Nov. 21, 2016 8:58 AM ETBioLineRx Ltd. (BLRX) StockBy: Douglas W. House, SA News Editor
  • BioLineRx (NASDAQ:BLRX) in-licenses a novel anti-inflammatory treatment for dry eye syndrome (DES) from Hebrew University of Jerusalem. The product candidate, BL-1230, is the third project in the company's strategic collaboration with Novartis Pharma AG (NVS).
  • BL-1230 is a selective cannabinoid receptor type 2 (CB2R) agonist. BioLineRx plans to explore its use in treating systemic inflammatory conditions as well.
  • The financial terms of the license are not disclosed.

Recommended For You

More Trending News

About BLRX Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
BLRX--
BioLineRx Ltd.